BLB&B Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$464K Buy
5,126
+21
+0.4% +$1.76K 0.02% 191
2026
Q1
$409K Sell
5,105
-44
-0.9% -$3.63K 0.02% 198
2025
Q4
$439K Sell
5,149
-5
-0.1% -$410 0.02% 198
2025
Q3
$401K Buy
5,154
+623
+14% +$48.7K 0.02% 200
2025
Q2
$354K Sell
4,531
-28
-0.6% -$2.09K 0.02% 208
2025
Q1
$330K Buy
4,559
+400
+10% +$28.6K 0.02% 217
2024
Q4
$308K Sell
4,159
-361
-8% -$25.3K 0.02% 223
2024
Q3
$298K Buy
4,520
+400
+10% +$29.1K 0.02% 230
2024
Q2
$381K Hold
4,120
0.02% 198
2024
Q1
$394K Hold
4,120
0.02% 201
2023
Q4
$314K Hold
4,120
0.02% 206
2023
Q3
$285K Hold
4,120
0.02% 198
2023
Q2
$389K Sell
4,120
-527
-11% -$45.8K 0.03% 177
2023
Q1
$384K Sell
4,647
-796
-15% -$62.6K 0.03% 168
2022
Q4
$406K Hold
5,443
0.03% 171
2022
Q3
$450K Hold
5,443
0.04% 156
2022
Q2
$518K Hold
5,443
0.04% 151
2022
Q1
$641K Buy
5,443
+53
+1% +$5.95K 0.04% 144
2021
Q4
$698K Sell
5,390
-170
-3% -$19.8K 0.05% 145
2021
Q3
$629K Hold
5,560
0.04% 161
2021
Q2
$576K Hold
5,560
0.04% 160
2021
Q1
$465K Sell
5,560
-320
-5% -$27.1K 0.04% 171
2020
Q4
$536K Buy
5,880
+720
+14% +$59.7K 0.04% 165
2020
Q3
$412K Hold
5,160
0.04% 170
2020
Q2
$357K Hold
5,160
0.04% 188
2020
Q1
$324K Hold
5,160
0.04% 194
2019
Q4
$401K Hold
5,160
0.04% 198
2019
Q3
$378K Buy
5,160
+480
+10% +$33.7K 0.04% 203
2019
Q2
$288K Hold
4,680
0.03% 229
2019
Q1
$298K Hold
4,680
0.04% 227
2018
Q4
$239K Hold
4,680
0.03% 244
2018
Q3
$272K Hold
4,680
0.03% 253
2018
Q2
$227K Sell
4,680
-1,800
-28% -$84K 0.03% 270
2018
Q1
$301K Hold
6,480
0.04% 241
2017
Q4
$243K Hold
6,480
0.03% 258
2017
Q3
$236K Hold
6,480
0.04% 262
2017
Q2
$255K Hold
6,480
0.04% 243
2017
Q1
$203K Hold
6,480
0.03% 267
2016
Q4
$202K Hold
6,480
0.04% 273
2016
Q3
$260K Hold
6,480
0.05% 240
2016
Q2
$215K Buy
+6,480
New +$222K 0.04% 247

Other funds holding EW

BLB&B Advisors's EW Position: Q2 2026 in Review

BLB&B Advisors increased its Edwards Lifesciences (EW) stake by 0.41% in Q2 2026, buying an estimated $1.76K and bringing the position to 5,126 shares worth $464K. The position accounts for 0.02% of the portfolio, ranked #191.

BLB&B Advisors first reported a position in EW in Q2 2016 and has held it in 41 quarters since. The position peaked at $698K in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • BLB&B Advisors held 5,126 shares of Edwards Lifesciences worth $464K as of Q2 2026.
  • BLB&B Advisors bought 21 Edwards Lifesciences shares in Q2 2026, an estimated $1.76K.
  • Edwards Lifesciences made up 0.02% of BLB&B Advisors's portfolio in Q2 2026, its #191 holding.
  • BLB&B Advisors first reported a position in Edwards Lifesciences in Q2 2016 and has held it in 41 quarters since.
  • BLB&B Advisors's Edwards Lifesciences position peaked at $698K in Q4 2021.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on BLB&B Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.